

ASSOCIATION BETWEEN THE DEVELOPMENT OF IMMUNE-RELATED ADVERSE EVENTS AND THE EFFECTIVENESS OF IPIIMUMAB IN ADVANCED MELANOMA

Hernández Ramos JA¹, Cortijo Cascajares S, Caro Teller JM, Bruni Montero MA, Ortiz Pérez S, Sánchez Sanz B, González Gómez A, Ferrari Piquero JM

Servicio de Farmacia – Hospital Universitario 12 de Octubre, 28041 Madrid (Spain)
¹jhernandezr@salud.madrid.org

BACKGROUND AND IMPORTANCE


Development of immune-related adverse events (irAE) might be associated with more successful outcomes in oncological patients treated with immunotherapeutic agents, such as nivolumab and pembrolizumab. However, scant information on ipilimumab is available.

AIM AND OBJECTIVES

- To study the **association between irAE incidence and the effectiveness of ipilimumab** in monotherapy for patients diagnosed with locally advanced or metastatic melanoma.
- To **analyse and describe the incidence of the irAE experienced** by these patients.



MATERIALS AND METHODS

Retrospective, observational and longitudinal study in a tertiary care hospital.



RESULTS

Sex	64.1% Male	35.9% Female
Age	61 Years (54 – 72.5)	
ECOG	0 – 1: 97.4%	≥ 2: 2.6%



CONCLUSION AND RELEVANCE

Development of irAE was associated with higher OS in our patients. This finding was specially noticeable in cases experiencing only one irAE or with moderate severity (grade 2). Further research is needed to elucidate if these results are statistically significant.

REFERENCES

- Otsuka M, Sugihara S, Mori S, Hamada K, Sasaki Y, Yoshikawa S, et al. *Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.* J Dermatol. 2020;47(4):356–62.
- Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. *Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial.* JAMA Oncol. 2020;6(4):519–27.